Veracyte (VCYT) released fresh data from the randomized BALANCE study at ASTRO 2025, showing its PAM50 molecular signature can identify which prostate cancer patients benefit from adding hormone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback